Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-08-06
2011-10-25
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S295000
Reexamination Certificate
active
08044054
ABSTRACT:
The present invention provides stereoisomers and stereoisomeric mixtures of 3-aminocarbonyl-bicycloheptene-2,4-pyrimidinediamine compounds having antiproliferative activity, compositions comprising the compounds and methods of using the compounds to inhibit cellular proliferation and to treat proliferate diseases such as tumorigenic cancers.
REFERENCES:
patent: 5962312 (1999-10-01), Plowman et al.
patent: 5972676 (1999-10-01), Plowman et al.
patent: 6207401 (2001-03-01), Plowman et al.
patent: 6342503 (2002-01-01), Aldrich et al.
patent: 6593326 (2003-07-01), Bradbury et al.
patent: 6841579 (2005-01-01), Plowman et al.
patent: 6908920 (2005-06-01), Thomas et al.
patent: 7060827 (2006-06-01), Singh et al.
patent: 2003/0139435 (2003-07-01), Ahmed et al.
patent: 2003/0162802 (2003-08-01), Guo et al.
patent: 2003/0171359 (2003-09-01), Dahmann et al.
patent: 2004/0029902 (2004-02-01), Singh et al.
patent: 2004/0102630 (2004-05-01), Brumby et al.
patent: 2004/0224966 (2004-11-01), Brumby et al.
patent: 2004/0265852 (2004-12-01), Plowman et al.
patent: 2005/0002938 (2005-01-01), Plowman et al.
patent: 2005/0113398 (2005-05-01), Argade et al.
patent: 2005/0176743 (2005-08-01), Luecking et al.
patent: 2005/0203114 (2005-09-01), Armistead et al.
patent: 2005/0209224 (2005-09-01), Singh et al.
patent: 2005/0209230 (2005-09-01), Singh et al.
patent: 2005/0234049 (2005-10-01), Singh et al.
patent: 2006/0025410 (2006-02-01), Singh et al.
patent: 2006/0035916 (2006-02-01), Singh et al.
patent: 2006/0040955 (2006-02-01), Singh et al.
patent: 2006/0058292 (2006-03-01), Singh et al.
patent: 2006/0058525 (2006-03-01), Singh et al.
patent: 2006/0135543 (2006-06-01), Singh et al.
patent: 2006/0167254 (2006-07-01), Cooper et al.
patent: 95/10506 (1995-04-01), None
patent: 97/22702 (1997-06-01), None
patent: 00/03032 (2000-01-01), None
patent: 01/60816 (2001-08-01), None
patent: 02/04429 (2002-01-01), None
patent: 02/059110 (2002-08-01), None
patent: 02/096888 (2002-12-01), None
patent: 02/102313 (2002-12-01), None
patent: 03/002544 (2003-01-01), None
patent: 03/026664 (2003-04-01), None
patent: 03/030909 (2003-04-01), None
patent: 03/032997 (2003-04-01), None
patent: 03/040141 (2003-05-01), None
patent: 03/055489 (2003-07-01), None
patent: 2004/014382 (2004-02-01), None
patent: 2005/035507 (2005-04-01), None
patent: 2005/037800 (2005-04-01), None
patent: 2005/118544 (2005-12-01), None
patent: 2006/078846 (2006-07-01), None
Gura, Systems for identifying New Drugs Are Often Faulty, Cancer Models, Science, vol. 278, No. 5340, pp. 1041-1042, Nov. 1997.
Johnson et al., Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials, British Journal of Cancer (2001) 64(10): 1424-1431.
Simone, Oncology: Introduction, Cecil Textbook of Medicine, 20thEdition, vol. 1, pp. 1004-1010, 1996.
Rogers et al., PubMed Abstract (J Cell Biol. 157(2):219-29) Epub Apr. 2002.
Tanaka et al., PubMed Abstract (Cell. 108(3):317-29), Feb. 2002.
International Search Report for PCT/US2005/041359 mailed Mar. 29, 2006.
International Search Report for PCT/US2005/041276 dated Jul. 12, 2006.
Search Report from GB0523012.3 dated Mar. 23, 2006.
Adam et al., “Synthesis of Optically Active α-Methylene β-Lactams Through Lipase-Catalyzed Kinetic Resolution,” J. Org. Chem., 65:4919-4922 (2000).
Forro et al., “Direct and Indirect Enzymatic Methods for the Preparation of Enatiopure Cyclic β-Amino Acids and Derivatives from β-Lactams,” Mini-Reviews in Organic Chemistry, 1(1):93-102 (2004).
Kurokawa et al., “Both Enantiomers of N-Boc-indoline-2-carboxylic Esters,” Bull. Chem. Soc., Jpn., 77:1021-1025 (2004).
Parker et al., “Enhancement of Candida Antarctica Lipase B Enantioselectivity and Activity in Organic Solvents,” Chem. Commun., 2247-2248 (1998).
Torre et al., “Lipase Catalysed Michael Addition of Secondary Amines to Acrylonitrile,” Chem. Commun., 1724-1725 (2004).
Cuiper, Anne Dite, “Molecular Docking with Candida Antarctica Lipase B,” Enantioselective Synthesis of Lactams and Lactones: a Chemo-Enzymatic Approach, Chpt. 10, 133-140 (1999), http://dissertations.ub.rug.nl/oai/.
Lin-Yu Lu et al.: “Aurora A Is Essential for Early Embryonic Development and Tumor Suppression,” Journal of Biological Chemistry, vol. 283, No. 46, Nov. 14, 2008, pp. 31785- 31790.
Elizabeth A. Harrington et al.: “VX-680, a potent and selective small-molecule inhibitor of he aurora kinases, suppresses tumor growth in vivo,” Nature Medicine, vol. 10, No. 3, Mar. 2004, pp. 262-267.
Argade Ankush
Li Hui
Singh Rajinder
McDonnell Boehnen & Hulbert & Berghoff LLP
Rao Deepak
Rigel Pharmaceuticals Inc.
Young Travis
LandOfFree
Stereoisomerically enriched 3-aminocarbonyl bicycloheptene... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Stereoisomerically enriched 3-aminocarbonyl bicycloheptene..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Stereoisomerically enriched 3-aminocarbonyl bicycloheptene... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4265449